Literature DB >> 10717719

Risk factors for death rattle in terminally ill cancer patients: a prospective exploratory study.

T Morita1, J Tsunoda, S Inoue, S Chihara.   

Abstract

Death rattle is frequently observed in cancer patients whose death is impending and may contribute to the severe distress of patients and their family members. To identify risk factors for development and persistency of death rattle, a prospective study was performed on 245 hospice inpatients. One-hundred-and-seven patients (44%) developed death rattle, 71% of whom achieved satisfactory symptom palliation until death. A multiple regression analysis identified neoplasms of brain and lung as independent risk factors for development of death rattle, while refractory symptoms were significantly associated with pulmonary neoplasms and infection/oedema. In conclusion, development of death rattle was influenced by both brain and lung malignancies, while its persistency was mainly determined by pulmonary pathology. A clinical classification of death rattle based on these factors would be established by a further confirmatory study.

Entities:  

Mesh:

Year:  2000        PMID: 10717719     DOI: 10.1191/026921600670897377

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   4.762


  9 in total

Review 1.  Death rattle: critical review and research agenda.

Authors:  Sebastiano Mercadamte
Journal:  Support Care Cancer       Date:  2013-11-20       Impact factor: 3.603

Review 2.  [Recommendations for death rattle].

Authors:  T Pastrana; H Reineke-Bracke; F Elsner
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

Review 3.  "The death rattle" in the intensive care unit after withdrawal of mechanical ventilation in neurological patients.

Authors:  Erwin J O Kompanje
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

4.  [Efficacy of glycopyrronium bromide and scopolamine hydrobromide in patients with death rattle: a randomized controlled study].

Authors:  Rudolf Likar; Ernst Rupacher; Hans Kager; Mario Molnar; Wofgang Pipam; Reinhard Sittl
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

5.  Effect of Prophylactic Subcutaneous Scopolamine Butylbromide on Death Rattle in Patients at the End of Life: The SILENCE Randomized Clinical Trial.

Authors:  Harriëtte J van Esch; Lia van Zuylen; Eric C T Geijteman; Esther Oomen-de Hoop; Bregje A A Huisman; Heike S Noordzij-Nooteboom; Renske Boogaard; Agnes van der Heide; Carin C D van der Rijt
Journal:  JAMA       Date:  2021-10-05       Impact factor: 56.272

6.  Scopolaminebutyl given prophylactically for death rattle: study protocol of a randomized double-blind placebo-controlled trial in a frail patient population (the SILENCE study).

Authors:  Harriëtte J van Esch; Lia van Zuylen; Esther Oomen-de Hoop; Agnes van der Heide; Carin C D van der Rijt
Journal:  BMC Palliat Care       Date:  2018-09-07       Impact factor: 3.234

7.  Identification and evaluation of observational measures for the assessment and/or monitoring of level of consciousness in adult palliative care patients: A systematic review for I-CAN-CARE.

Authors:  Anna-Maria Krooupa; Bella Vivat; Stephen McKeever; Elena Marcus; Joseph Sawyer; Paddy Stone
Journal:  Palliat Med       Date:  2019-08-22       Impact factor: 5.713

Review 8.  [The anesthetist's view on Jethro Tull's Aqualung].

Authors:  K Lewandowski
Journal:  Anaesthesist       Date:  2021-03       Impact factor: 1.041

9.  Understanding relatives' experience of death rattle.

Authors:  Harriëtte J van Esch; Martine E Lokker; Judith Rietjens; Lia van Zuylen; Carin C D van der Rijt; Agnes van der Heide
Journal:  BMC Psychol       Date:  2020-06-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.